PALATINE, Ill., Aug. 6, 2009 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) (Acura) announced today that we have submitted a briefing package to the U.S. Food and Drug Administration (FDA) addressing the issues raised in the FDA's June 30, 2009 Complete Response Letter ("CRL") related to the New Drug Application (NDA) for Acurox(R) (oxycodone HCl/niacin) Tablets. Acura and King Pharmaceuticals Research and Development, Inc (King) are scheduled to meet with the FDA in late third quarter 2009 to discuss the CRL and the briefing package.
